Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002.
Karachunskiy A, Tallen G, Roumiantseva J, Lagoiko S, Chervova A, von Stackelberg A, Aleinikova O, Bydanov O, Bajdun L, Nasedkina T, Korepanova N, Kuznetsov S, Novichkova G, Goroshkova M, Litvinov D, Myakova N, Ponomareva N, Inyushkina E, Kondratchik K, Abugova J, Fechina L, Arakaev O, Karelin A, Lebedev V, Judina N, Scharapova G, Spichak I, Shamardina A, Ryskal O, Shapochnik A, Rumjanzew A, Boos J, Henze G; ALL-MB study group.
Karachunskiy A, et al.
J Cancer Res Clin Oncol. 2019 Apr;145(4):1001-1012. doi: 10.1007/s00432-019-02854-x. Epub 2019 Mar 6.
J Cancer Res Clin Oncol. 2019.
PMID: 30840197
Free PMC article.
Clinical Trial.
One major component of this regimen included a total of 18 doses of weekly intramuscular (IM) native Escherichia coli-derived asparaginase (E. coli-ASP) at 10000 U/m(2) during three consolidation courses. ...
One major component of this regimen included a total of 18 doses of weekly intramuscular (IM) native Escherichia coli-derived asparag …